SEOM–GEICO clinical guideline on epithelial ovarian cancer (2023)
-
José Alejandro Perez Fidalgo [1] ; Fernando Gálvez Montosa [2] ; Eva María Guerra [3] ; Ainhoa Madariaga [10] ; Aranzazu Manzano [4] ; Cristina Martin Lorente [5] ; Maria Jesús Rubio Pérez [6] ; Jesus Alarcón [7] ; María Pilar Barretina Ginesta [8] ; Lydia Gaba [9]
-
[1] Universitat de València
Universitat de València
Valencia, España
-
[2] Hospital Universitario de Jaén
Hospital Universitario de Jaén
Jaén, España
-
[3] Hospital Ramón y Cajal
Hospital Ramón y Cajal
Madrid, España
-
[4] Hospital Clínico San Carlos de Madrid
Hospital Clínico San Carlos de Madrid
Madrid, España
-
[5] Hospital de la Santa Creu i Sant Pau
Hospital de la Santa Creu i Sant Pau
Barcelona, España
-
[6] Hospital Universitario Reina Sofia
Hospital Universitario Reina Sofia
Cordoba, España
-
[7] Hospital Universitario Son Espases
Hospital Universitario Son Espases
Palma de Mallorca, España
-
[8] Universitat de Girona
Universitat de Girona
Gerona, España
-
[9] Universitat de Barcelona
Universitat de Barcelona
Barcelona, España
-
[10] Department of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 11, 2024, págs. 2758-2770
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
In recent years, the incorporation of new strategies to the therapeutic armamentarium has completely changed the outcomes of epithelial ovarian cancer (EOC). The identifcation of new predictive and prognostic biomarkers has also enabled the selection of those patients more likely to respond to targeted agents. Nevertheless, EOC is still a highly lethal disease and resistance to many of these new agents is common. The objective of this guideline is to summarize the most relevant strategies to manage EOC, to help the clinician throughout the challenging diagnostic and therapeutic processes and to provide evidence-based recommendations.
